BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
|
By LabMedica International staff writers Posted on 07 Aug 2019 |

Image: The Bact/Alert Virtuo diagnostic solution (Photo courtesy of BioMérieux).
BioMérieux (Marcy-l'Étoile, France) showcased its unique and comprehensive range of diagnostic solutions that support the responsible use of antibiotics to improve patient care at AACC 2019. Among its diagnostic solutions highlighted at the tradeshow was Bact/Alert Virtuo, which along with bioMérieux’s Bact/Alert Virtuo blood culture system and Bact/Alert Fan Plus media, provides fast and actionable results for better antimicrobial stewardship.
BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.
At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.
BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.
BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.
At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.
BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- Sysmex America Exhibits New Products, Automation and Quality Solutions
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more









